How do vaccines interact with cosentyx therapy?

How do vaccines work during Cosentyx treatment?

Cosentyx blocks IL-17A, a cytokine involved in immune signaling. This dampens certain inflammatory pathways that psoriasis, psoriatic arthritis, and ankylosing spondylitis rely on. Because IL-17 also helps defend against some bacteria and fungi, the same blockade can reduce the body’s ability to clear certain infections.

Live vaccines carry a theoretical risk of causing disease in anyone whose immune response is altered. Cosentyx prescribing information recommends avoiding live vaccines while on therapy and for at least 16 weeks after stopping. Inactivated or non-live vaccines, including annual influenza shots and pneumococcal vaccines, are generally considered safe, but their protective effect may be weaker.

What happens to vaccine effectiveness when IL-17 is blocked?

Clinical studies show measurable drops in antibody levels after some non-live vaccines in patients taking secukinumab. For example, responses to hepatitis B and pneumococcal vaccines were lower than in untreated controls. Physicians often check antibody titers before starting Cosentyx or advise an extra vaccine dose if titers remain low.

Why are companies challenging this patent?

Cosentyx’s core patents on IL-17A antibodies expire in 2025–2027 in major markets. Several biosimilar developers have filed abbreviated biologics license applications and patent challenges to clear a path for earlier market entry. Ongoing litigation centers on formulation patents and manufacturing methods rather than the primary antibody sequence.

When does exclusivity expire?

The FDA granted Cosentyx seven years of orphan-drug exclusivity for certain pediatric indications that ends in 2030. Basic compound patents and regulatory data exclusivity are expected to lapse between late 2025 and 2027, opening the door for biosimilar competition in adult use.

Can biosimilars enter before patent expiry?

Under the Biologics Price Competition and Innovation Act, biosimilars may file four years after original approval and launch after 12 years unless blocked by patents. Several manufacturers have already settled or are negotiating entry dates that fall shortly after the primary patent cliff in 2026–2027.

What side effects are patients asking about?

Common reports involve upper-respiratory infections, oral or genital candidiasis, and injection-site reactions. Patients also frequently ask about new or worsening inflammatory bowel disease, a known IL-17 class effect, and whether vaccines can trigger flares.

[1] Novartis Pharmaceuticals. Cosentyx (secukinumab) Prescribing Information. 2024.
[2] DrugPatentWatch.com. Cosentyx Patent and Exclusivity Data. https://www.drugpatentwatch.com/drug/Cosentyx
[3] Mease PJ et al. Vaccine immunogenicity in secukinumab-treated patients. Ann Rheum Dis. 2021.